耐多药肺结核合并 HIV 感染患者中，利福平抗结核治疗时 CYP2B6 516TT 基因型者出现依非韦伦血药浓度升高的矛盾现象。
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
机构信息
The Miriam Hospital, Providence, Rhode Island 02906, USA.
出版信息
AIDS. 2011 Jan 28;25(3):388-90. doi: 10.1097/QAD.0b013e3283427e05.
Abstract
Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G→T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype.
摘要
在利福平含结核病（TB）治疗期间，一些个体的依非韦伦血浆浓度升高，与利福平预期的诱导作用相反。在未接受（n = 38）和接受利福平含治疗的 HIV 感染患者中（n = 18），我们检验了药物-基因相互作用可能解释这种高度可变的药物相互作用的假设。双向方差分析显示 CYP2B6 516G→T 多态性与利福平含治疗之间存在显著相互作用，表明可能需要根据患者的基因型来个体化调整依非韦伦剂量。
相似文献
1
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.耐多药肺结核合并 HIV 感染患者中，利福平抗结核治疗时 CYP2B6 516TT 基因型者出现依非韦伦血药浓度升高的矛盾现象。
AIDS. 2011 Jan 28;25(3):388-90. doi: 10.1097/QAD.0b013e3283427e05.
2
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.CYP2B6基因G516T多态性而非利福平合用对印度南部人类免疫缺陷病毒感染患者中依非韦伦的稳态药代动力学有影响。
Antimicrob Agents Chemother. 2009 Mar;53(3):863-8. doi: 10.1128/AAC.00899-08. Epub 2009 Jan 5.
3
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.接受含依非韦伦的抗逆转录病毒治疗（cART）且接受或未接受含利福平的抗结核治疗的HIV-1感染非洲患者的神经精神表现。
Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.
4
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.CYP2B6 基因型，但不是利福平为基础的抗结核联合治疗，解释了长期依非韦伦血浆暴露的变异性。
Pharmacogenomics. 2014 Aug;15(11):1423-35. doi: 10.2217/pgs.14.73.
5
Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.在撒哈拉以南非洲地区，接受基于利福平的抗结核治疗的同时，是否需要增加依非韦伦的剂量？HIV-TB药物基因组研究。
Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.
6
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.利福平及 CYP2B6 基因型对 HIV 合并结核病及非结核病患者长期依非韦伦自动诱导及其血药浓度的影响
Clin Pharmacol Ther. 2011 Sep;90(3):406-13. doi: 10.1038/clpt.2011.129. Epub 2011 Aug 3.
7
High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.在接受抗结核治疗的乌干达合并结核分枝杆菌/人类免疫缺陷病毒感染的成年人中，CYP2B6 516 TT 基因型者的依非韦伦血清浓度较高。
J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.
8
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.依非韦伦或利福平与异烟肼治疗 HIV 或结核病时与左炔诺孕酮紧急避孕的药物遗传学相互作用。
Pharmacogenet Genomics. 2023 Aug 1;33(6):126-135. doi: 10.1097/FPC.0000000000000501. Epub 2023 Jun 12.
9
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.遗传多态性在细胞色素 P450 中的作用以及结核分枝杆菌共治疗对 CYP2B6 SNPs 预测值的影响及其对成年 HIV 患者依非韦伦血药浓度的影响。
Antiviral Res. 2014 Feb;102:44-53. doi: 10.1016/j.antiviral.2013.11.011. Epub 2013 Dec 5.
10
Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.基于利福平的抗结核治疗方案联合给药对埃塞俄比亚患者中依非韦伦和8-羟基依非韦伦药代动力学参数的长期影响。
J Clin Pharmacol. 2016 Dec;56(12):1538-1549. doi: 10.1002/jcph.756. Epub 2016 May 29.
引用本文的文献
1
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.人细胞色素 P450 家族 1、2、3 作为药物代谢基因，重点介绍其抗疟和抗结核药物及常见的非洲等位基因。
Int J Mol Sci. 2023 Feb 8;24(4):3383. doi: 10.3390/ijms24043383.
2
A review of clinical pharmacogenetics Studies in African populations.非洲人群临床药物遗传学研究综述。
Per Med. 2020 Mar;17(2):155-170. doi: 10.2217/pme-2019-0110. Epub 2020 Mar 3.
3
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.人群和药物遗传学变异对抗结核联合治疗期间依非韦伦药代动力学和免疫结局的影响：撒哈拉以南非洲两个群体的平行前瞻性队列研究
Front Pharmacol. 2020 Feb 7;11:26. doi: 10.3389/fphar.2020.00026. eCollection 2020.
4
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.一线抗结核治疗对三岁以下儿童奈韦拉平药代动力学的影响。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00839-19. Print 2019 Oct.
5
Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.提升结核病研究进展的能力；第三届国际研究项目进展报告会议论文集
Tuberculosis (Edinb). 2018 Dec;113:153-162. doi: 10.1016/j.tube.2018.09.009. Epub 2018 Oct 1.
6
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.坦桑尼亚艾滋病毒和艾滋病毒/结核病患者中，具有相同 CYP2B6*6 基因型的患者，长期依非韦伦药代动力学无显著差异。
Sci Rep. 2018 Nov 5;8(1):16316. doi: 10.1038/s41598-018-34674-3.
7
Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line.替诺福韦和恩曲他滨与依法韦仑联合使用不会调节依法韦仑对人淋巴母细胞系线粒体功能和胆固醇生物合成的抑制作用。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00691-18. Print 2018 Sep.
8
Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.人类对活动性和潜伏性结核病易感性的遗传学：现有知识和未来展望。
Lancet Infect Dis. 2018 Mar;18(3):e64-e75. doi: 10.1016/S1473-3099(17)30623-0. Epub 2017 Oct 27.
9
Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis.两名接受稳定抗逆转录病毒治疗的男性在开始抗结核治疗后出现了男性乳房发育。
Malawi Med J. 2016 Dec;28(4):185-187. doi: 10.4314/mmj.v28i4.8.
10
Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.在艾滋病临床试验组A5202方案中，对随机开始抗逆转录病毒治疗方案的患者进行的多表型关联研究。
Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.
本文引用的文献
1
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.依非韦伦的体外和体内初级及次级代谢：鉴定新的代谢途径和细胞色素 P450 2A6 作为依非韦伦 7-羟化的主要催化剂。
Drug Metab Dispos. 2010 Jul;38(7):1218-29. doi: 10.1124/dmd.109.031393. Epub 2010 Mar 24.
2
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.CYP2B6、CYP2A6 和 UGT2B7 基因多态性是 HIV 感染患者中依非韦伦中剂量浓度的预测因子。
AIDS. 2009 Oct 23;23(16):2101-6. doi: 10.1097/QAD.0b013e3283319908.
3
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.抗逆转录病毒药物依非韦伦经UGT2B7的葡萄糖醛酸化作用及与齐多夫定药物相互作用的体外研究
Drug Metab Dispos. 2009 Sep;37(9):1793-6. doi: 10.1124/dmd.109.027706. Epub 2009 Jun 1.
4
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.细胞色素P450 2B6（c.516G→T）和细胞色素P450 2A6（*9B和/或*17）基因多态性是HIV感染患者中依非韦伦血浆浓度的独立预测指标。
Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.
5
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.在一名接受利福平治疗的患者中，将依非韦伦剂量减至每日一次200毫克。
AIDS. 2009 Mar 27;23(6):742-4. doi: 10.1097/QAD.0b013e32832914a3.
6
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.对CYP2A6功能受损个体中依非韦伦代谢的体内分析。
Pharmacogenet Genomics. 2009 Apr;19(4):300-9. doi: 10.1097/FPC.0b013e328328d577.
7
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.利福平对合并结核病的HIV感染儿童中依非韦伦药代动力学的影响。
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3.
8
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.依法韦仑在有或无利福平使用情况下，在HIV阳性患者中的多剂量药代动力学。
Curr HIV Res. 2007 May;5(3):349-53. doi: 10.2174/157016207780636588.
9
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.在接受结核病和艾滋病毒治疗的患者中，每日服用600毫克依非韦伦并联合利福平，会导致血药浓度高度可变，但临床疗效良好。
J Antimicrob Chemother. 2006 Dec;58(6):1299-302. doi: 10.1093/jac/dkl399. Epub 2006 Oct 10.
10
Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring.一种用于检测HIV蛋白酶抑制剂阿扎那韦与其他8种抗逆转录病毒药物联用情况的分析方法的全面验证及其在治疗药物监测中的适用性。
Ther Drug Monit. 2006 Aug;28(4):517-25. doi: 10.1097/00007691-200608000-00006.
Zotero 插件